Fulgent Genetics (FLGT) Cash from Investing Activities (2015 - 2026)

Fulgent Genetics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting $50.8 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 4.87% year-over-year to $50.8 million; the TTM figure through Jun 2026 stood at $92.0 million (up 46.78% YoY), while the FY2025 annual figure was $111.4 million, up 290.86% from the prior year.
• Cash from Investing Activities came in at $50.8 million for Q2 2026 at Fulgent Genetics, up from $10.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $53.4 million in Q2 2025 to a low of -$213.7 million in Q2 2022.
• Average Cash from Investing Activities over 5 years is -$6.0 million, with a median of $10.0 million recorded in 2024.
• The largest YoY upside for Cash from Investing Activities was 766.42% in 2024 against a maximum downside of 983.74% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$92.6 million in 2022, then soared by 126.21% to $24.3 million in 2023, then tumbled by 213.12% to -$27.5 million in 2024, then surged by 140.63% to $11.2 million in 2025, then jumped by 355.45% to $50.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $50.8 million in Q2 2026, $10.9 million in Q1 2026, and $11.2 million in Q4 2025.